Metraipolis › archive › dc_f0a2c14d25cd

Immunometabolic integration in therapeutic strategies for managing MASLD — Europe PMC PMID:41293239

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41293239
DOI
10.3389/fphar.2025.1693753
License (as archived)
solo-consultazione
Archived
2026-11-08T16:51:27.362Z
SHA-256 of the archived text
742cb7f7e37735f6af21d5690934fc246705373ecc01167114f0a9870737348a
Stable URL of this page
https://metraipolis.com/documento/dc_f0a2c14d25cd

How to cite

Immunometabolic integration in therapeutic strategies for managing MASLD — Europe PMC PMID:41293239 — Europe PMC (en), https://europepmc.org/article/MED/41293239 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f0a2c14d25cd (Metraipolis archive dc_f0a2c14d25cd, sha256 742cb7f7e37735f6af21d5690934fc246705373ecc01167114f0a9870737348a)
BibTeX
@misc{dcf0a2c14d25cd,
  title = {Immunometabolic integration in therapeutic strategies for managing MASLD — Europe PMC PMID:41293239},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41293239},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f0a2c14d25cd; sha256 742cb7f7e37735f6af21d5690934fc246705373ecc01167114f0a9870737348a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41293239. Agents can read the archived copy with the MCP tool read_document.